Bemiparin: A Review of its Use in the Prevention of Venous Thromboembolism and Treatment of Deep Vein Thrombosis

Drugs

Volumn 63, Issue 21, 2003, Pages 2357-2377

  Chapman, Therese M ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Bemiparin; Deep vein thrombosis; DVT; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Venous thromboembolism

Indexed keywords

BADYKET; BEMIPARIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; D DIMER; DALTEPARIN; ENOXAPARIN; HEPARIN; IVOR; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE; PROTEIN C; PROTHROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; WARFARIN; ZIBOR;

AREA UNDER THE CURVE; BLEEDING; BOLUS INJECTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; COST MINIMIZATION ANALYSIS; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; EUROPE; HEALTH CARE COST; HEMATOMA; HIGH RISK PATIENT; HOSPITAL COST; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL STANDARD UNIT; PHARMACODYNAMICS; POSTOPERATIVE HEMORRHAGE; PROPHYLAXIS; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; SPINAL CORD HEMORRHAGE; SURGICAL PATIENT; THROMBOEMBOLISM; THROMBUS; TOTAL HIP PROSTHESIS; VEIN THROMBOSIS;

AREA UNDER CURVE; ECONOMICS, PHARMACEUTICAL; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; RANDOMIZED CONTROLLED TRIALS; TISSUE DISTRIBUTION; VENOUS THROMBOSIS;

THROMBUS;

EID: 0142248246     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363210-00009     Document Type: Review

References (45)

1. Anderson FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107: 19-116
2. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: 14-8
3. Scottish Intercollegiate Consensus Guidelines Network. Prophylaxis of venous thromboembolism: a national clinical guideline [online]. Available from URL: http://www.sign. ac.uk/pdf/sign62.pdf [Accessed 2003 Sep 16]
4. Vaughn P, Gardner J, Peters F, et al. Risk factors for venous thromboembolism in general surgical patients. Isr Med Assoc J 2002; 4: 1037-9
5. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001 Jan; 119 (1 Suppl.): 132S-75S
6. Morris TA. Heparin and low molecular weight heparin: background and pharmacology. Clin Chest Med 2003; 24: 39-47
7. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S-94S
8. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997 Sep 4; 337 (10): 688-98
9. Samama MM, Bara L, Gerotziafas GT. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 1994; 24: 105-17
10. Rovi Pharmaceutical Laboratories. Hibor (bemiparin sodium): summary of product characteristics. Madrid: Rovi Pharmaceutical Laboratories, 2002 Jun
11. Kakkar VV, Howes J, Sharma V, et al. A comparative, double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. Thromb Haemost 2000 Apr; 83 (4): 523-9
12. Rovi Pharmaceutical Laboratories. Phivor 25,000 IU (bemiparin sodium): final proposed summary of product characteristics. Madrid: Rovi Pharmaceutical Laboratories, 2003 Mar
13. Falkon L, Saenz-Campos D, Antonijoan R, et al. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11) - a three way cross-over study in healthy volunteers. Thromb Res 1995; 78 (1): 77-86
14. Falkon L, Gari M, Barbanoj M, et al. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, bemiparin, at therapeutic subcutaneous doses. Blood Coagul Fibrinolysis 1998 Mar; 9 (2): 137-41
15. Falkon L, Bayes M, Frontera G, et al. Pharmacokinetics and tolerability of a new low molecular mass heparin (RO-11) in healthy volunteers - a dose-finding study within the therapeutical range. Thromb Haemost 1997 Jan; 77 (1): 133-6
16. Moreno Gonzalez E, Fontcuberta J, de la Llama F, et al. Prophylaxis of thromboembolic disease with RO-11 (ROVI), during abdominal surgery. Hepatogastroenterology 1996; 43: 744-7
17. Falkon L, Gari M, Gich I, et al. In vitro and ex vivo neutralizing effect of protamine sulphate on the anticoagulant activity of a new low molecular mass heparin. Thromb Res 1998; 89: 79-83
18. Antonijoan RM, Borrell M, Zsolt I, et al. Interaction between protamine sulfate and a new LMWH at therapeutic doses in healthy volunteers: bemiparin 7500 IU [abstract]. 18th Congress of the International Society of Thrombosis and Haemostasis; 2001 Jul 6-12; Paris
19. Falkon L, Gari M, Saenz-Campos D, et al. Kinetic behaviour of the TFPI and anti-FXa effects, after the injection of a LMWH (RO-11) in healthy subjects. Thromb Haemost 1995 Apr; 73 (4): 728-9
20. Westmuckett AD, Kakkar VV, Hamuro T, et al. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro. Thromb Haemost 2001 Dec; 86 (6): 1547-54
21. Martinez M, Vaya A, Lopez-Camacho C, et al. High and low molecular weight heparins do not modify red blood cell aggregability in vitro. Clin Haemorheol Microcirc 2000; 23: 67-70
22. Perez-Ruiz A, Montes R, Carrasco P, et al. Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium. Clin Applied Thromb Hemost 2002; 8 (1): 65-71
23. De Lorenzo F, Newberry D, Scully M, et al. Low molecular weight heparin (bemiparin sodium) and the coagulation profile of patients with heart failure. Am Heart J 2002 Apr; 143 (4): 689-94
24. Morita S, Gebska MA, Kakkar AK, et al. High affinity binding of heparin by necrotic tumour cells neutralises anticoagulant activity: implications for cancer related thromboembolism and heparin therapy. Thromb Haemost 2001; 86: 616-22
25. Gebska MA, Titley I, Paterson HF, et al. High-affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death. Blood 2002 Mar 15; 99 (6): 2221-7
26. Borrell M, Antonijoan RM, Ortin R, et al. Pharmacokinetic profiles of two LMWH: bemiparin 3500 IU and enoxaparin 4000 IU after subcutaneous administration in healthy volunteers [abstract]. 18th Congress of the International Society of Thrombosis and Haemostasis; 2001 Jul 6-12; Paris
27. Depasse F, Gonzalez de Suso MJ, Lagoutte I, et al. Comparative study of the pharmacokinetic profiles of two LMWHs -bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa) - administered subcutaneously to healthy male volunteers. Thromb Res 2003; 109: 109-17
28. Hidalgo M, Figueroa JM. Prophylaxis of venous thromboembolism in abdominal wall surgery. Hernia 2000; 4: 242-7
29. Fenollosa J, Seminario P. Efficacy and safety of bemiparin in the prophylaxis of venous thromboembolism in orthopedic surgery [in Spanish]. Revista De Ortopedia y Traumatologia 2001; 45 (6): 460-5
30. Planes A, Vochelle N, Gonzalez De Suso MJ, et al. Prophylactic antithrombotic therapy after orthopedic surgery with bemiparin, a second-generation low molecular weight heparin (in Spanish]. Rev Esp Anestesiol Reanim 2001; 48 (6): 258-63
31. Navarro-Quilis A, Castellet E, Rocha E, et al. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. J Thromb Haemost 2003; 1: 425-32
32. Bonal J, Gisbert R. Pharmacoeconomic analysis of prophylaxis for thromboembolic disease in hip replacement patients [in Spanish]. Rev Espa Farmacoecon 2000 Mar, 17-26
33. Kakkar VV, Gebska M, Kadziola Z, et al. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost 2003; 89: 674-80
34. Ferriols-Lisart R, Ferriols-Lisart F, Jimenez-Torres V. Effectiveness and safety of bemiparin versus low-molecular weight heparins in orthopaedic surgery. Pharm World Sci 2002 Jun; 24 (3): 87-94
35. Rovi Pharmceutical Laboratories. Data on file. 2003
36. Prandoni P. The treatment of venous thromboembolic disorders: new challenges and opportunities. Haematologica 2003 May; 88 (5): 610-3
37. Brown DFM. Treatment options for deep venous thrombosis. Emerg Med Clin North Am 2001 Nov; 19 (4): 913-23
38. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119: 176S-93S
39. Institute for Clinical Systems Improvement. ICSI health care guideline: venous thromboembolism [online]. Available from URL: http://www.icsi.org/ knowledge/detail.asp?catID=29& itemid=202 [Accessed 2003 Jul 11]
40. Prandoni P. Heparins and venous thromboembolism: current practice and future directions. Thromb Haemost 2001 Jul; 86 (1): 488-98
41. McKay GA, Paterson KR. Low molecular weight heparins - a safer option than unfractionated heparin? Adv Drug Reactions Toxicol Rev 2001; 20 (4): 256-76
42. Lumpkin MM. FDA public health advisory. Anesthesiology 1998; 88: 27A-8A
43. Tryba M. European practice guidelines: thromboembolism prophylaxis and regional anesthesia. Reg Anesth Pain Med 1998; 23 (6 Suppl. 2): 178-82
44. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British national formulary (BNF). London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2003
45. Sweetman SC. Martindale: The complete drug reference. 33rd ed. London: Pharmaceutical Press, 2002